

The attached chart is a proposed program funding timeline for the remaining funds to be committed (approximately \$1,562,900,000). Each year, the Governing Board should be presented the financial strategic plan to allow for reexamination and reallocation of priorities. This chart is solely for purposes of discussion and provides a basic backbone and overview of the Agency's program in years 2011 to 2017.

The estimated funds available for program commitments in years 2011-2107 is calculated as follows:

\$	3,000,000,000	Total General Obligation Bond Authorized
\$	1,177,100,000	Estimated Commitments thru December 2010
\$	180,000,000	General & Grants Administration
\$	50,000,000	Capitalized Interest/Cost of Issuance
\$	30,000,000	General reserves and direct legal costs
<u>\$</u>	<u>1,437,100,000</u>	<u>Total estimated committed funds, operations, and general reserves/direct legal costs</u>

\$	1,562,900,000	Estimated funds available for program commitments (2011-2017)	
-----------	----------------------	--	--

PROPOSED RFA FUNDING TIMELINE 2011-2017

RFA	Governing Board Estimated Approval Date**	Calendar Year that Funding Starts	Estimated Commitment Amount
Tools and Technology 2*	Jan-Mar 2011	2011	\$40,000,000
Research Leadership 4*	Jan-Mar 2011	2011	\$5,600,000
Clinical Trials*	Apr-June 2011	2011	\$50,000,000
Research Leadership 5*	Apr-June 2011	2011	\$5,600,000
Basic Biology 3*	July-Sept 2011	2011	\$45,000,000
Research Leadership 6*	July-Sept 2011	2011	\$5,600,000
Disease Team 2 Planning*	July-Sept 2011	2011	\$3,300,000
Research Leadership 7 & 8* ^a	Oct-Dec 2011	2011	\$11,200,000
Shared Labs 2	Oct-Dec 2011	2012	\$30,000,000
Total Committed Funds 2011			\$196,300,000
Early Translational 3	Jan-Mar 2012	2012	\$80,000,000
Bridges 2	Apr-June 2012	2012	\$25,000,000
Training 3	Apr-June 2012	2012	\$45,000,000
Disease Team 2 Award*	Apr-June 2012	2012	\$240,000,000
Basic Biology 4	Oct-Dec 2012	2013	\$45,000,000
Total Committed Funds 2012			\$435,000,000
Tools and Technology 3	Jan-Mar 2013	2013	\$30,000,000
IPS - banking	Jan-Mar 2013	2013	\$25,000,000
Early Translational 4	Apr-June 2013	2013	\$80,000,000
Disease Team 3 Planning	July-Sept 2013	2013	\$3,300,000
To Be Determined 1	Oct-Dec 2013	2014	\$30,000,000
Total Committed Funds 2013			\$168,300,000
Basic Biology 5	Jan-Mar 2014	2014	\$35,000,000
Disease Team 3 Award	July-Sept 2014	2014	\$200,000,000
Early Translational 5	July-Sept 2014	2014	\$60,000,000
To Be Determined 2	Oct-Dec 2014	2015	\$30,000,000
Total Committed Funds 2014			\$325,000,000
Basic Biology 6	Jan-Mar 2015	2015	\$35,000,000
Disease Team 4 Planning	July-Sept 2015	2015	\$3,300,000
To Be Determined 3 ^b	July-Sept 2015	2015	\$85,000,000
Floating Reserve ^b	July-Sept 2015	2015	\$50,000,000
Early Translational 6	Oct-Dec 2015	2016	\$60,000,000
Total Committed Funds 2015			\$233,300,000
To Be Determined 4 ^b	Apr-June 2016	2016	\$35,000,000
Disease Team 4 Award	July-Sept 2016	2016	\$200,000,000
To Be Determined 5 ^c	July-Sept 2016	2016	\$30,000,000
Total Committed Funds 2016			\$265,000,000
To Be Determined 6 ^c	Jan - Mar 2017	2017	\$40,000,000
To Be Determined 7 ^c	Apr- June 2017	2017	\$40,000,000
To Be Determined 8 ^c	Apr- June 2017	2017	\$50,000,000
Total Committed Funds 2017			\$130,000,000
Total RFA Cashflow Commitments including \$190M Estimated Recovered Funds (2011-2017)			\$1,752,900,000
Total Net Funds Available for Cash Flow Commitments of \$190M Recovered Funds (2011-2017)			\$1,562,900,000

^a Research Leadership Award funds all likely expended in calendar year 2011

^b TBD funds can be designated into one or more RFAs and a \$50M floating reserve fund can supplement any program as appropriate

^c Estimated undisbursed funds of \$190M is divided into \$60M for 2016 and \$130M for 2017

^{bc} Candidate categories that the President wishes to discuss with the Board include programs such as alpha stem cell clinic program, a stem cell genomics program, and additional funds for clinical trials.

* Concept Approved RFA's

**Cash Disbursements Start Approx. 3 Months Post Governing Board Approval